

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	:	
<b>John Erbey et al.</b>	:	Examiner: Shahnam J. Sharareh
	:	
Serial No.: 10/700,909	:	Group Art Unit: 1617
	:	
Filed: November 4, 2003	:	Date: January 18, 2005
	:	
For: <b>Methods and Therapeutic</b>	:	
<b>Combinations for the</b>	:	
<b>Treatment of Autoimmune</b>	:	
<b>Disorders</b>	:	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these reference(s) ☒ are attached ☐ were filed in related application U.S. Serial No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively.

(a) No fee is believed due because:

- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ This Supplemental Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

I hereby certify that this correspondence is being transmitted via facsimile addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, facsimile number 703-872-9306 on January 18, 2005.

Chris Reichert  
(Name of Person Faxing Paper)

  
Signature

1/18/2005  
Date

- (b) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (c) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Supplemental Information Disclosure Statement, or credit any overpayment to Deposit Account No. 23-0650, Patent Case No. CV06093US01.

Respectfully submitted,

Dated: January 18, 2005

By:   
Ann Marie Cannoni  
Reg. No. 36, 972  
Webb Ziesenheim Logsdon  
Orkin & Hanson, P.C.  
Attorney for Applicant  
700 Koppers Building  
436 Seventh Avenue  
Pittsburgh, PA 15219  
Telephone: (412) 471-8815  
Facsimile: (412) 471-4094  
E-mail: webblaw@webblaw.com

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2001. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/700,909
				Filing Date	November 4, 2003
				First Named Inventor	John Erbey et al.
				Group Art Unit	1617
				Examiner Name	Shahnam J. Sharareh
Sheet	1	of	2	Attorney Docket Number	CV06093US/4686-050109

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup>			
		N/A				

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
	1	WO	99/22728	A1	Arch Development Corporation	May 14, 1999		
	2	WO	01/96347	A1	Bristol-Myers Squibb Company	December 20, 2001		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2001. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/700,909
				Filing Date	November 4, 2003
				First Named Inventor	John Erbey et al.
				Group Art Unit	1617
				Examiner Name	Shahnam J. Sharareh
				Attorney Docket Number	CV06093/4686-050109
Sheet	2	of	2		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T <sup>2</sup>
	3	Luis Gruberg, MD, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive Protein (CRP) and Chlamydia," American Heart Association Scientific Sessions 2000.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**TRANSMITTAL LETTER**

MAIL STOP AMENDMENT  
 Commissioner for Patents  
 P. O. Box 1450  
 Alexandria, VA 22313-1450

Application No.: 10/700,909 Filing Date: November 4, 2003  
 Examiner: Mark L. Berch Art Unit: 1617  
 Invention: **METHODS AND THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS**


Transmitted via facsimile herewith is a Request for Reconsideration in the above-identified application.

- ☐ Small Entity Status is/has been asserted for this application under 37 CFR 1.27.  
☐ A verified statement to establish small entity status under 37 CFR 1.27 is enclosed.  
☒ No additional claim fee is required.  
☐ The fee has been calculated as shown below:

No of Claims After Amendment	Highest No. Previously Paid For	Present Extra	Small Entity Rate	Non-Small Entity Rate	Charge
Total <u>26</u>	<u>26</u>	<u>0</u>	x \$ 25.00	x \$ 50.00	\$ <u>0.00</u>
Indep. <u>5</u>	<u>5</u>	<u>0</u>	x \$100.00	x \$200.00	\$ <u>0.00</u>
First Presentation of Multiple Dependent Claim/s			+ \$	+ \$	\$ <u>0.00</u>
TOTAL ADDITIONAL FEE					\$ <u>0.00</u>

- ☐ Check in the amount of \$\_\_\_\_\_ is enclosed for one-month extension of time.  
☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication to Deposit Account No. 23-0650. Please refund any overpayment to Deposit Account No. 23-0650. An original and two copies of this sheet are enclosed.  
☒ Any additional filing fees required under 37 CFR 1.16.  
☒ Any patent application processing fees under 37 CFR 1.17.

January 18, 2005  
 Date

By:   
 Ann Marie Cannoni  
 Registration No. 35,972  
 Webb Ziesenheim Logsdon Orkin  
 & Hanson, P.C.  
 Attorney for Applicant  
 700 Koppers Building  
 436 Seventh Avenue  
 Pittsburgh, PA 15219-1818  
 Telephone: (412) 471-8815  
 Facsimile: (412) 471-4094  
 E-mail: webblaw@webblaw.com